NetworkNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Senior Medical Tech Veteran as New President
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has appointed Robert Eno to the newly created position of president. A senior medical technology executive, Eno will work to enhance the company’s strategic and operations capabilities. Eno brings a background of almost three decades experience in developing markets and commercializing disruptive medical technologies to his new role, where he will be essential in the company’s strategic direction, commercialization efforts, and day-to-day operations. Eno noted that he believes HeartBeam’s technology will be able to make a major impact on the lives of the millions of people who suffer from cardiac-related issues. In previous positions, which included CEO of Preview Medical Inc. and senior VP for Heartflow Inc., Eno has created go-to-market strategies for an array of breakthrough products including noninvasive FFR CT (“FFR CT”) diagnostic for coronary artery disease, laser cataract surgery, scanning retinal laser photocoagulation and intravascular brachytherapy. He has led all aspects of marketing and product functions for a new category of personalized, noninvasive testing for heart disease and has held senior marketing and sales leadership roles at OptiMedica, NeoGuide Systems and Avantec Vascular. “We have a tremendous opportunity to accelerate our company growth as we move forward on our commercialization path, and we’re excited to have Rob join our leadership team,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “Rob has extensive experience bringing innovative medical technology products to market, which will be invaluable as we move forward with plans to broaden our product portfolio pipeline.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has appointed Robert Eno to the newly created position of president. A senior medical technology executive, Eno will work to enhance the company’s strategic and operations capabilities. Eno brings a background of almost three decades experience in developing markets and commercializing disruptive medical technologies to his new role, where he will be essential in the company’s strategic direction, commercialization efforts, and day-to-day operations. Eno noted that he believes HeartBeam’s technology will be able to make a major impact on the lives of the millions of people who suffer from cardiac-related issues. In previous positions, which included CEO of Preview Medical Inc. and senior VP for Heartflow Inc., Eno has created go-to-market strategies for an array of breakthrough products including noninvasive FFR CT (“FFR CT”) diagnostic for coronary artery disease, laser cataract surgery, scanning retinal laser photocoagulation and intravascular brachytherapy. He has led all aspects of marketing and product functions for a new category of personalized, noninvasive testing for heart disease and has held senior marketing and sales leadership roles at OptiMedica, NeoGuide Systems and Avantec Vascular. “We have a tremendous opportunity to accelerate our company growth as we move forward on our commercialization path, and we’re excited to have Rob join our leadership team,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “Rob has extensive experience bringing innovative medical technology products to market, which will be invaluable as we move forward with plans to broaden our product portfolio pipeline.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
